Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBITDA (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed EBITDA for 3 consecutive years, with -$20.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 25.32% to -$20.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$83.6 million through Dec 2025, down 27.08% year-over-year, with the annual reading at -$83.6 million for FY2025, 27.08% down from the prior year.
  • EBITDA for Q4 2025 was -$20.8 million at Artiva Biotherapeutics, up from -$21.4 million in the prior quarter.
  • The five-year high for EBITDA was $11.4 million in Q3 2023, with the low at -$21.4 million in Q3 2025.
  • Average EBITDA over 3 years is -$14.6 million, with a median of -$17.3 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 251.05% in 2024, then decreased 18.53% in 2025.
  • Over 3 years, EBITDA stood at -$12.0 million in 2023, then tumbled by 38.47% to -$16.6 million in 2024, then fell by 25.32% to -$20.8 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$20.8 million, -$21.4 million, and -$21.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.